Quick Answer
FENNEC PHARMACEUTICALS INC. reported Operating Income Loss of -$6.28 million for the year ending 2025.
- FENNEC PHARMACEUTICALS INC. showed a decrease of -344.6% in Operating Income Loss from 2024 to 2025.
- This data is from FENNEC PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: -$944.0 thousand | Q1 2012: -$616.0 thousand | Q2 2012: -$1.25 million | Q3 2012: -$630.0 thousand | Q1 2013: -$537.0 thousand | Q2 2013: -$927.0 thousand | Q3 2013: -$51.0 thousand | Q1 2014: -$537.0 thousand | Q2 2014: -$930.0 thousand | Q3 2014: -$619.0 thousand | Q1 2015: -$452.0 thousand | Q2 2015: -$549.0 thousand | Q3 2015: -$338.0 thousand | Q1 2016: -$454.0 thousand | Q2 2016: -$707.0 thousand | Q3 2016: -$564.0 thousand | Q1 2017: -$771.0 thousand | Q2 2017: -$1.48 million | Q3 2017: -$2.19 million | Q1 2018: -$1.79 million | Q2 2018: -$2.67 million | Q3 2018: -$2.85 million | Q1 2019: -$2.68 million | Q2 2019: -$4.81 million | Q3 2019: -$1.86 million | Q1 2020: -$3.84 million | Q2 2020: -$4.85 million | Q3 2020: -$5.86 million | Q1 2021: -$4.92 million | Q2 2021: -$3.92 million | Q3 2021: -$4.17 million | Q1 2022: -$3.55 million | Q2 2022: -$5.01 million | Q3 2022: -$7.90 million | Q1 2023: -$5.27 million | Q2 2023: -$4.67 million | Q3 2023: -$1.02 million | Q1 2024: $13.74 million | Q2 2024: -$5.04 million | Q3 2024: -$5.20 million | Q1 2025: -$808.0 thousand | Q2 2025: -$2.73 million | Q3 2025: -$189.0 thousand.
- Over the full 16 years of available data (2010 to 2025), FENNEC PHARMACEUTICALS INC.'s Operating Income Loss has declined by 36.4%.
- Historical annual values: Fiscal year 2025: -$6.28 million | Fiscal year 2024: $2.57 million | Fiscal year 2023: -$12.77 million | Fiscal year 2022: -$22.59 million | Fiscal year 2021: -$17.22 million | Fiscal year 2020: -$17.89 million | Fiscal year 2019: -$13.01 million | Fiscal year 2018: -$10.41 million | Fiscal year 2017: -$6.95 million | Fiscal year 2016: -$2.87 million | Fiscal year 2015: -$1.89 million | Fiscal year 2014: -$2.88 million | Fiscal year 2013: -$1.93 million | Fiscal year 2012: -$3.62 million | Fiscal year 2011: -$3.44 million | Fiscal year 2010: -$4.60 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: